yingweiwo

Fibrin

Cat No.:V64521 Purity: ≥98%
Fibrin is an insoluble protein extracted from bovine blood that is produced in response to bleeding.
Fibrin
Fibrin Chemical Structure CAS No.: 9001-31-4
Product category: Others 12
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
50mg
100mg
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Product Description
Fibrin is an insoluble protein extracted from bovine blood that is produced in response to bleeding. Fibrin is a major component of blood clots and is used to clot the blood.
Biological Activity I Assay Protocols (From Reference)
References

[1]. The anti-parasitic agent suramin and several of its analogues are inhibitors of the DNA bindingprotein Mcm10. Open Biol. 2019 Aug 30;9(8):190117.

Additional Infomation
Fibrin is a peptide.
A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Weight
0
Exact Mass
145.085
CAS #
9001-31-4
PubChem CID
439199
Appearance
White to yellow solid powder
Density
1.146g/cm3
Boiling Point
471.7ºC at 760mmHg
Flash Point
239.1ºC
Index of Refraction
1.48
LogP
0.188
Hydrogen Bond Donor Count
3
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
3
Heavy Atom Count
10
Complexity
135
Defined Atom Stereocenter Count
0
InChi Key
BWGVNKXGVNDBDI-UHFFFAOYSA-N
InChi Code
InChI=1S/C5H11N3O2/c1-7-5(10)3-8-4(9)2-6/h2-3,6H2,1H3,(H,7,10)(H,8,9)
Chemical Name
2-amino-N-[2-(methylamino)-2-oxoethyl]acetamide
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
H2O: < 0.1 mg/mL
DMSO: < 1 mg/mL
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Efficacy of polyglycolic acid sheets and fibrin glue for patients with continuous low-dose aspirin
CTID: UMIN000026051
Phase:    Status: Complete: follow-up complete
Date: 2017-02-27
A validation study of local steroid injection therapy with endoscopic tissue shielding method using polyglycolic sheet and fibrin glue for the prevention of stricture after entire circumferential esophageal endoscopic submucosal dissection (PF-E)
CTID: UMIN000025447
Phase:    Status: Complete: follow-up continuing
Date: 2017-01-01
Polyglycolic acid sheets with fibrin glue during endoscopic submucosal dissection of gastric and duodenal tumors
CTID: UMIN000021614
Phase:    Status: Complete: follow-up complete
Date: 2016-03-25
Endoscopic closure of gastrointestinal fistula using polyglycolic acid sheets with fibrin glue
CTID: UMIN000019619
Phase: Phase I,II    Status: Recruiting
Date: 2015-11-04
Endoscopic closure of postsurgical esphageal fistula using polyglycolic acid sheets with fibrin glue
CTID: UMIN000019622
Phase: Phase I,II    Status: Recruiting
Date: 2015-11-04
View More

Utility of autologous fibrin glue for prevention of delayed bleeding of gastric endoscopic submucosal dissection under antithrombotic therapy
CTID: UMIN000019386
Phase:    Status: Recruiting
Date: 2015-10-16


Intervention study about the additive infusion of concentrated fibrinogen preparation and the amount of blood transfusion for the massive hemorrhage case
CTID: UMIN000019027
Phase:    Status: Recruiting
Date: 2015-09-15
The efficacy of endoscopic tissue shielding method with polyglycolic acid (PGA) sheets and fibrin glue for the prevention of delayed bleeding after colorectal endoscopic submucosal dissection in patients taking antithrombotic therapy. -multicenter randomized control study-
CTID: UMIN000016832
Phase:    Status: Recruiting
Date: 2015-04-01
Clinical evaluation for the effects of intraocular tissue plasminogen activator administration in various eye diseases
CTID: UMIN000015726
Phase:    Status: Recruiting
Date: 2014-11-21
Exploratory clinical study concerning the efficacy of 'steroid injection' and 'shielding method with polyglycolic acid sheets and fibrin glue' for the prevention of postoperative stricture after esophageal endoscopic submucosal dissection of superficial esophageal neoplasms.
CTID: UMIN000015532
Phase:    Status: Complete: follow-up complete
Date: 2014-10-26
Pancreatic fistula following laparoscopic splenectomy: impact of fibrin glue and polyglycolic acid felt on prophylaxis of postoperative complication.
CTID: UMIN000015507
Phase:    Status: Complete: follow-up complete
Date: 2014-10-23
Randomized Controlled Trial to assess the efficacy of a shielding method that utilises polyglycolic acid(PGA) sheets and fibrin glue to prevent bleeding after endoscopic submucosal dissection (ESD) for gastric neoplasms
CTID: UMIN000015091
Phase: Phase III    Status: Complete: follow-up complete
Date: 2014-09-09
The efficacy of endoscopic tissue shielding method with polyglycolic acid(PGA) sheets and fibrin glue for the prevention of delayed bleeding after endoscopic submucosal dissection in patients on anticoagulation therapy
CTID: UMIN000013993
Phase:    Status: Recruiting
Date: 2014-06-01
The efficacy of endoscopic tissue shielding method with polyglycolic acid(PGA) sheets and fibrin glue for the prevention of delayed bleeding after endoscopic submucosal dissection in patients on antiplatelet therapy.
CTID: UMIN000013990
Phase:    Status: Recruiting
Date: 2014-06-01
Evaluation of sheet type fibrin sealant in patients who underwent retroperitoneal lymph node dissection
CTID: UMIN000013646
Phase:    Status: Recruiting
Date: 2014-04-07
Intrapleural administration of fibrin glue for intractable pneumothorax
CTID: UMIN000011000
PhaseNot applicable    Status: Recruiting
Date: 2013-06-20
Randomized controlled trial of bronchial occlusion methods in intractable pneumothorax or bronchopleural fistula
CTID: UMIN000009774
Phase:    Status: Complete: follow-up complete
Date: 2013-01-14
Treatment of fibrin formation with intraocular tissue plasminogen activator
CTID: UMIN000006430
Phase: Phase II,III    Status: Pending
Date: 2011-09-28
Intrapleural administration of sustained-release basic fibroblast growth factor in patients with chronic obstructive pulmonary disease accompanied by pneumothorax
CTID: UMIN000004276
Phase: Phase II    Status: Complete: follow-up complete
Date: 2010-12-01
Fibrin sealing with PGA felt for prevention of bleeding and bile leakage after liver resection
CTID: UMIN000003324
Phase:    Status: Complete: follow-up complete
Date: 2010-03-20
Reduction of post-operative pain by PGA sheet attachment to wound after tonsillectomy
CTID: UMIN000002853
Phase:    Status: Complete: follow-up complete
Date: 2010-01-01

Contact Us